MerTK is a novel therapeutic target in gastric cancer

Introduction The role of MerTK has not been assessed in gastric cancer (GC). The aim of this study was to identify a subgroup of GC patients with MerTK tumor overexpression, and to evaluate MerTK as a potential therapeutic target in this disease. Methods Protein and mRNA expression of MerTK were evaluated, and other various in vitro analyses including shRNA transfection, cell cycle anslysis, MTS assay and colony forming assay were carried out with GC cell lines and GC patient-derived cells (PDCs). Results shRNA-mediated knockdown of MerTK resulted in inhibition of cell growth, as well as increased cellular apoptosis in MerTK positive GC cells. Out of 192 GC patients, 16 (8.3%) patients showed strong protein expression and they had a significantly shorter overall survival compared to those with no MerTK expression. In 54 cases of GC PDCs, 4 cases (7.4%) showed mRNA overexpression, which was comparable to the protein expression rate. When we administered UNC1062, a novel MerTK-selective small molecular tyrosine kinase inhibitor, proliferation of MerTK overexpressing GC cells and PDCs were considerably inhibited. Conclusion MerTK may be involved in GC carcinogenesis, and it could be a potential novel therapeutic target in GC patients.

[1]  Joon-Oh Park,et al.  Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Shin,et al.  Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[3]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[4]  D. Newton,et al.  UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor , 2014, Journal of medicinal chemistry.

[5]  A. Pierce,et al.  MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme , 2014, Oncotarget.

[6]  A. Ullrich,et al.  The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells , 2014, Nature.

[7]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[8]  Melissa A. Sandahl,et al.  MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. , 2013, The Journal of clinical investigation.

[9]  T. Boggon,et al.  MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL , 2013, Pigment cell & melanoma research.

[10]  S. Frye,et al.  UNC1062, a new and potent Mer inhibitor. , 2013, European journal of medicinal chemistry.

[11]  G. Ferry,et al.  S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab , 2013, Molecular Cancer Therapeutics.

[12]  C. Miller,et al.  MERTK receptor tyrosine kinase is a therapeutic target in melanoma. , 2013, The Journal of clinical investigation.

[13]  H. Earp,et al.  Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia , 2013, Oncogene.

[14]  W. Franklin,et al.  Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer , 2012, Oncogene.

[15]  Bin Tean Teh,et al.  Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes , 2012, Nature Genetics.

[16]  Khay Guan Yeoh,et al.  A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets , 2012, Gut.

[17]  Anupam Verma,et al.  Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. , 2011, ACS medicinal chemistry letters.

[18]  Zhengyan Kan,et al.  Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer , 2011, Nature Genetics.

[19]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[20]  D. Bearss,et al.  Targeting Axl and Mer Kinases in Cancer , 2011, Molecular Cancer Therapeutics.

[21]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[22]  A. Thorburn,et al.  Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity , 2010, Molecular Cancer Therapeutics.

[23]  A. Luttun,et al.  Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. , 2010, Blood.

[24]  Bjørn Tore Gjertsen,et al.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.

[25]  G. Feldmann,et al.  The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target , 2009, Cancer biology & therapy.

[26]  C. Bokemeyer,et al.  Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Ullrich,et al.  Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[28]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[29]  S. Al-Batran,et al.  Chemotherapy for advanced gastric cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. Seno,et al.  Growth arrest‐specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway , 2007, Molecular carcinogenesis.

[31]  R. Tisch,et al.  Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. , 2007, Blood.

[32]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. Meltesen,et al.  Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase , 2006, Oncogene.

[34]  H. Snodgrass,et al.  Ectopic Expression of the Proto-oncogene Mer in Pediatric T-Cell Acute Lymphoblastic Leukemia , 2006, Clinical Cancer Research.

[35]  Stephen T. C. Wong,et al.  Multiple roles for the receptor tyrosine kinase axl in tumor formation. , 2005, Cancer research.

[36]  D. Cunningham,et al.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  John R. Mackey,et al.  Gastric Adenocarcinoma: Review and Considerations for Future Directions , 2005, Annals of surgery.

[38]  J. Curtis,et al.  The receptor tyrosine kinase MerTK activates phospholipase C γ2 during recognition of apoptotic thymocytes by murine macrophages , 2004, Journal of leukocyte biology.

[39]  M. Ehinger,et al.  Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. , 2002, Cancer research.

[40]  C. Chi,et al.  Clinical significance of AXL kinase family in gastric cancer. , 2002, Anticancer research.

[41]  R. Scott,et al.  Phagocytosis and clearance of apoptotic cells is mediated by MER , 2001, Nature.

[42]  J. Weber,et al.  Expression of the receptor protein‐tyrosine kinases Tyro‐3, Axl, and Mer in the developing rat central nervous system , 2000, The Journal of comparative neurology.

[43]  P. Godowski,et al.  Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation , 1997, Oncogene.

[44]  H. Kung,et al.  Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase , 1995, Molecular and cellular biology.

[45]  H. Snodgrass,et al.  Cloning and Mrna Expression Analysis of a Novel Human Protooncogene, C-merr , 2022 .

[46]  B. Mayer,et al.  A novel oncogene, v-ryk, encoding a truncated receptor tyrosine kinase is transduced into the RPL30 virus without loss of viral sequences , 1992, Journal of virology.

[47]  H. Earp,et al.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.

[48]  Stage Iiia,et al.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer , 2005 .

[49]  D. Bereczki,et al.  The Cochrane Database of Systematic Reviews , 2003 .

[50]  HighWire Press.  Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research. , 2002 .

[51]  H. Kung,et al.  Protein-tyrosine kinase and protein-serine/threonine kinase expression in human gastric cancer cell lines. , 1998, Journal of biomedical science.